(Reuters) – Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Consolidation therapy is given to cancer patients…
Source:Seattle Genetics, Takeda’s cancer drug meets main goal in trial
Monday, September 29, 2014
Seattle Genetics, Takeda's cancer drug meets main goal in trial
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment